Mind Body Intervention for Long COVID-19
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeth Israel Deaconess Medical Center
About this trial
The goal of this study is to determine if a mind-body intervention can help people suffering from symptoms associated with Long COVID. The study is a randomized trial examining the effectiveness of a mind body intervention in reducing somatic symptoms from Long COVID in participants as compared to usual care and an active control (second mind body intervention). The investigators will secondarily investigate whether the intervention alleviates individual somatic complaints and improves daily functioning, relative to usual care and the active control
Eligibility criteria
Qualifiers
Adult (≥ 18 years of age)
Infection with Sars-COV2 (i. e., positive antibody, antigen, or PCR testing)
Symptoms attributed only to COVID-19 and not to known comorbid disease (e.g., other infections, cancer, etc)
A somatic symptom score ≥ 10 on the SSS-8 questionnaire with involvement of at least 3 domains
Disqualifiers
Clear diagnosis of physical disease (e.g. lung fibrosis, myocarditis) not inclusive of non-specific findings such as mild arthritis
Hospitalization in an intensive care unit for acute COVID-19 infections
Age greater than 65 years
Diagnosis of dementia or similar cognitive impairment
Trial design
Treatments tested in this trial
- Mind Body Intervention #1
Treatment groups
180 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov